Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising prostate cancer combo trial halted before results

NCT ID NCT01995058

Terminated Disease control Sponsor: Exelixis Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested two drugs—cabozantinib and abiraterone—together in 54 men with castration-resistant prostate cancer that had spread to bones. The goal was to see if the combination could delay cancer growth. However, the study was stopped early by the sponsor for business reasons, so no effectiveness data were collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cabozantinib and abiraterone (with prednisone)
What this could lead to
If it had worked, this combination could have slowed cancer progression in men with advanced prostate cancer that has spread to bones.
What could go wrong
The trial was terminated early for business reasons, so no results are available. It is unclear if the combination is safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CANCER PROSTATE CANCER PROSTATIC NEOPLASMS

Contacts and locations

Locations

  • Study site

    Scottsdale, Arizona, 85258, United States

  • Study site

    Sedona, Arizona, 86336, United States

  • Study site

    Tucson, Arizona, 85710, United States

  • Study site

    Oxnard, California, 93030, United States

  • Study site

    San Diego, California, 92108, United States

  • Study site

    Aurora, Colorado, 80012, United States

  • Study site

    Aurora, Colorado, 80045, United States

  • Study site

    Athens, Georgia, 30607, United States

  • Study site

    Atlanta, Georgia, 30318, United States

  • Study site

    Peoria, Illinois, 61615, United States

  • Study site

    Wichita, Kansas, 67214, United States

  • Study site

    Las Vegas, Nevada, 89148, United States

  • Study site

    Raleigh, North Carolina, 27607, United States

  • Study site

    Tualatin, Oregon, 97062, United States

  • Study site

    Charleston, South Carolina, 29414, United States

  • Study site

    Greenville, South Carolina, 29605, United States

  • Study site

    Myrtle Beach, South Carolina, 29572, United States

  • Study site

    Dallas, Texas, 75246, United States

  • Study site

    Houston, Texas, 77024, United States

  • Study site

    Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.